(RTTNews) - Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) Friday announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab), as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results